"March 7, 2013 -- An FDA panel voted to stop recommending calcitonin salmon for the treatment of osteoporosis in women who are at least five years past menopause.
The committee voted 12-9 against continued marketing of the drug, citing"...
MDP-25 Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
MDP-25 Kit for the Preparation of Technetium Tc 99m Medronate Injection is a diagnostic agent used as a bone imaging agent to delineate areas of altered osteogenesis. Common side effects include allergic reactions such as itching, various skin rashes, hypotension, chills, nausea, fever, and vomiting.
The recommended adult dose of MDP-25, after reconstitution with oxidant-free sodium pertechnetate Tc 99m, is 370 to 740 megabecquerels (10 to 20 millicuries [200 μCi/kg]) by slow intravenous injection over a period of 30 seconds. MDP-25 may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, MDP-25 should only be administered if prescribed. This drug passes into breast milk. Formula feedings should be substituted for breast feedings.
Our MDP-25 Kit for the Preparation of Technetium Tc 99m Medronate Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
MDP-25 FDA Prescribing Information: Side Effects
Several cases of allergic dermatological reactions have been reported in association with the use of Technetium Tc 99m Medronate.
Several reactions have also been reported in association with other radiopharmaceuticals of the diphosphonate class, particularly Technetium Tc 99m Medronate. These are usually hypersensitivity reactions characterized by itching, various skin rashes, hypotension, chills, nausea, fever, and vomiting. One death secondary to cardiac arrhythmia following the administration of Technetium Tc 99m Medronate has been reported. In addition, one case of cardiac arrest in a patient also undergoing pulmonary function testing one and one-half hours after the performance of a bone scan using Technetium Tc 99m Medronate has been reported.
Read the entire FDA prescribing information for MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate Injection)
Additional MDP-25 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips and advances in treatment.